http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-1114369-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dc04f5c89d8c275354dbd39188a766ff |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K8-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61Q5-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61Q5-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K8-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A45D7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-195 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-16 |
| filingDate | 1966-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1968-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-1114369-A |
| titleOfInvention | Amides of n-acyl cysteines |
| abstract | Novel compounds of formula <FORM:1114369/C2/1> where R1 and R2 are hydrogen or alkyl groups having 1-4 carbon atoms, R3 is hydrogen, or an alkyl, aralkyl or aryl group having up to 9 carbon atoms, -NR4R5 is piperidino, pyrrolidino, N1-R5-piperazino, morpholino, thiamorpholino, hexamethyleneimino, or amino wherein R4 is hydrogen, or an alkyl, alkenyl, cycloalkyl or cycloalkenyl group each having up to 5 carbon atoms and optionally substituted by 1 or 2 hydroxy groups, and R5 is hydrogen or an alkyl group having 1-4 carbon atoms which may be substituted by 1 or 2 hydroxy groups, are prepared (1) by reacting a compound of formula Q-S-CR1R2-CH(NH2)-CO2Y where Q is hydrogen or an easily removable protective group, and Y is hydrogen or an alkyl or p-nitrophenyl group, with an amine of formula R4R5NH, to form the corresponding propionamide, and with an acylating agent to form the N-acyl derivative, followed by removing the protective group if present, the reaction with the acylating agent and the removal of the protective group being carried out in any sequence, (2) by reducing the corresponding bis-N-acylcystine diamide, or (3) by reacting an N-acylcysteine with an amine R4R5NH in the presence of a dicycloalkylcarbodiimide. The bis-N-acylcystine diamides may be prepared by reacting an S-benzyl-N-acylcysteine amide with sodium and ammonia, or by treating a cystine dimethyl ester with an amine to form the diamide followed by acylation. 3 - Hexanoyl - 4 - dimethylcarbamoyl - 2,2,5, 5 - tetramethylthiazolidine is obtained by reacting 2,2,5,5 - tetramethyl - 4 - carboxythiazolidine with hexanoyl chloride in pyridine, and treating the N-hexanoylisopropylidene-penicillamine obtained with triethylamine, ethyl chloroformate and dimethylamine.ALSO:Mucin is lysed by contacting mucus with a compound of formula I <FORM:1114369/A5-A6/1> wherein R1 and R2 are hydrogen or C1-4 alkyl groups, R3 is hydrogen, or alkyl, aralkyl or aryl groups each having up to 9 carbon atoms, -NR4R5 is piperidino, pyrrolidino, N\sv-R5-piperazino, morpholino, thiamorpholino, hexamethyleneimino, or amino wherein R4 is hydrogen, or alkyl, alkenyl, cycloalkyl or cycloalkenyl groups each having up to 5 carbon atoms and is unsubstituted or substituted by up to 2 hydroxy groups, and R5 is hydrogen or C1-4 alkyl and is unsubstituted or substituted by up to 2 hydroxy groups. The Specification also discloses pharmaceutical compositions for use as nasal decongestants and in other respiratory conditions, e.g. as inhalants, and for other mucolytic uses, e.g. as vaginal tablets, containing certain of the active compounds of formula I above, if desired in combination with other active ingredients such as cetylpyridinium chloride and tyrothricin. The compounds are also useful in the treatment of heavy metal poisoning, and as potential radio-protective drugs, and may be incorporated in a barium enema for use in radiopaque therapy, and to liquefy human sputum to facilitate microscopic examination. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10590073-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11091433-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2020233602-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11548851-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11268964-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2018338103-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11753370-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019060623-A1 |
| priorityDate | 1965-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 61.